Joshua Brody: Impressive potency of chemo-free immunotherapy as 1st-line treatment for lymphoma

Joshua Brody, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute, shared on X:

“Impressive potency of chemo-free immunotherapy as 1st-line treatment for lymphoma with 85% complete remission rate… with thanks to the patients, families, and clinical research team at Mount Sinai Health System and around the world.”